JavaScript is disabled. Please enable to continue!
Services >> In Vitro Pharmacology >> Phosphatases

Screen with the industry’s first commercial available phosphatase profiling solution

Sidebar Image


Reversible protein phosphorylation is critical for normal cellular function with perturbations leading to diseases such as cancer. This post-translational modification alters protein function either by relocating proteins, changing protein interaction and/or modifying their enzymatic activity. Phosphatases are the key enzymes involved in removing phosphatase groups and thus reversing the effect of kinase directed phosphorylation. Although lagging behind kinases in maturity as a therapeutic drug class, interest is growing in phosphatases, like PTP-1B, as future therapeutic targets. As with kinases, phosphatase inhibitor specificity is a major challenge for drug discovery scientists.

Through the combined expertise of Cerep, Panlabs, and PhosphataseProfiler™ services, Eurofins has developed a robust, reliable, and well-characterized solution to screen your focused chemical libraries or profile your lead compounds for their inhibitory effects on phosphatases.


 Advantages of Phosphatase Profiling with Eurofins:

  • Over 40 available assays for selectivity profiling of novel chemical entities
  • Over 10 years of experience in phosphatase profiling
  • One week turnaround time available to drive SAR
  • Single point inhibition data or 10-point IC50 curves
  • Unmatched robustness and reproducibility



Figure 1. Profiling of phosphatase inhibitors using PhosphataseProfiler™.

Representative results from PhosphataseProfiler™ screening of six compounds against a panel of phosphatases shows targeted inhibition of PP1a, PP1b, and PP2A.